Current Treatment Research

NIH is supporting many clinical trials through its ACTIV initiative to test a variety of treatments and therapies for COVID-19.

Drugs to calm the immune system
COVID in lungs graphic

This study tests the safety and effectiveness of three medicines, called immune modulators, to minimize the effects of an overactive immune system response that some COVID-19 patients experience. This response, called a “cytokine storm,” can lead to acute respiratory distress syndrome, multiple organ failure, and other life-threatening complications. The clinical trial aims to determine if minimizing that immune response can reduce the need for ventilators and shorten hospital stays.

The ACTIV-1 Immune Modulators trials

Get involved in a clinical trial

Antibodies to lessen the severity of COVID-19
Scientific COVID-19 image

This clinical trial is enrolling adults with COVID-19 who are not hospitalized to evaluate safety, to understand if treatments can reduce the duration of symptoms, and to test if the treatment can increase the proportion of participants with undetectable virus.  

The ACTIV-2 Outpatient Monoclonal Antibodies study 

Clinical trials are also underway for people who are hospitalized with COVID-19 to evaluate investigational treatments for safety and efficacy in reducing time to recovery and effects on respiratory and non-respiratory complications. 

The ACTIV-3 Inpatient Therapies trials 

Find out how to get involved in a clinical trial 

Drugs to prevent blood clotting
COVID blood clotting

Three types of studies aim to determine if various types of medicines called blood thinners can treat adults diagnosed with COVID-19 and prevent life-threatening blood clots from forming. The studies focus on people who are diagnosed with COVID-19 but are not hospitalized, those who are hospitalized, and those who are recovering from COVID-19.

The ACTIV-4 Antithrombotics study

Repurposing medicine used to treat other conditions
Pharmacy shelves

Studies are currently enrolling people who are hospitalized with COVID-19 or are experiencing mild to moderate COVID-19 symptoms to test whether medicines already approved to treat other conditions can be used to also treat COVID-19.

Get information about the ACTIV-5 Big Effect Trial

Treatment Guidelines

Treatment Guidelines

The latest COVID-19 treatment guidelines, developed and updated regularly by a U.S. panel of experts

Treatment Resources

Monoclonal antibodies are being tested in NIH clinical trials as a potentia...

Learn how antibodies can be effective at preventing COVID-19, especially fo...

Information about what to do if you’ve tested positive for COVID-19 and wha...

Information about treatment options and clinical trials from HHS

Clinical trials offer hope for patients while helping researchers find bett...

Selected NIH-Published Research on Treatments

Grobler, J. A., Anderson, A. S., Fernandes, P., Diamond, M. S., Colvis, C. M., Menetski, J. P., . . . Carter, K. L, on behalf of the ACTIV Preclinical Working Group. (2020). Accelerated preclinical paths to support rapid development of COVID-19 therapeutics. Cell Host and Microbe, 28(5), 636645. doi:10.1016/j.chom.2020.09.017

Hewitt, J. A., Lutz, C., Florence, W. C., Pitt, M. L. M., Rao, S., Rappaport, J., & Haigwood, N.L., on behalf of the ACTIV Preclinical Working Group. (2020). ACTIVating resources for the COVID-19 pandemic: In vivo models for vaccines and therapeutics. Cell Host and Microbe, 28(5), 646659. doi:10.1016/j.chom.2020.09.016

Collins, F. S., & Stoffels, P. (2020). Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An unprecedented partnership for unprecedented times. JAMA, 323(24), 24552457. doi:10.1001/jama.2020.8920